AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34847900
Drug: Counseling with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling with hope therapy (8 sessions of 45 minutes, twice a week)
Trial: 36126255
Drug: Morphine-Midazolam (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine-Midazolam (5 mg each)
Trial: 35583116
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of antibiotics
Trial: 33184979
Drug: oral semaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral semaglutide (4-week dose escalation from 3 to 7 to 14 mg)
Trial: 38753273
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (CM)
Trial: 33023067
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d algal DHA
Trial: 35857132
Drug: Multi-strain probiotic
RxNorm normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-strain probiotic (Lactobacillus acidophilus UBLA‐34, L. rhamnosus UBLR‐58, L. reuteri UBLRu‐87 (2 billion CFU each), L. plantarum UBLP‐40, L. casei UBLC‐42, L. fermentum UBLF‐31, Bifidobacterium bifidum UBBB‐55 (1 billion CFU each) and fructo‐oligosaccharides (100 mg)) along with dietary and lifestyle modifications
Trial: 32490570
Drug: Tumor debulking
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor debulking followed by chemotherapy
Trial: 32490570
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with chemotherapy
Trial: 34951464
Drug: Dextroamphetamine (oral;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine (oral; 0.43 mg/kg)
Trial: 32382551
Drug: anti-VEGF treatment
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-VEGF treatment (ProReNata approach)
Trial: 36404400
Drug: Mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirabegron (50 mg daily, titrated to 200 mg daily, n=39)
Trial: 35620165
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa (twice or three times per week intravenous)
Trial: 35620165
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (once per week intravenous)
Trial: 34940699
Drug: Whole biomass
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole biomass of Phaeodactylum tricornutum (PT) at 5.3 g/day
Trial: 34940699
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) containing equal amounts of EPA and DHA (300 mg/day)
Trial: 35795994
Drug: Prehabilitation during
RxNorm normalized name: Pro-C-Dure 6 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehabilitation during neoadjuvant therapy
Trial: 35795994
Drug: Loss of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loss of VAT during neoadjuvant therapy
Trial: 34181148
Drug: Oxycodone-paracetamol (OPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone-paracetamol (OPT group)
Trial: 32154123
Drug: Paliperidone extended-release
RxNorm normalized name: Paliperidone Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone extended-release (oral, flexibly dosed, 1.5‐12 mg/day)
Trial: 32993832
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of a package of noncommunicable disease interventions including cardiovascular risk scoring, hypertension management, and statin treatment.
Trial: 34028130
Drug: Cold therapy
RxNorm normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold therapy before amniocentesis (group 1)
Trial: 34990968
Drug: Adjuvant clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant clonidine (0.2 mg/d to a maximum of 0.6 mg/d)
Trial: 33561199
Drug: Multi-factor experiment
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-factor experiment with a combination of surface area‐to‐volume ratio, oil density, and oil thickness
Trial: 33561199
Drug: Repeatability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeatability of identical treatments
Trial: 32171749
Drug: Step-by-step video
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-by-step video demonstration (1 to 2 hours preparation)
Trial: 35109502
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (monthly recreational session during the same period)
Trial: 34969609
Drug: Qualified practitioner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qualified practitioner Johrei treatment
Trial: 34510189
Drug: 67 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67 g/d of soy nuts providing ~25.5 g protein and 174 mg isoflavones
Trial: 34510189
Drug: 67 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 67 g/d of soy nuts
Trial: 35709019
Drug: Restrictive intravenous
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive intravenous fluid therapy
Trial: 35709019
Drug: Standard intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intravenous fluid therapy
Trial: 33196584
Drug: Self-administered daily
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered daily low-intensity pulsed ultrasound
Trial: 33439978
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe as ferrous fumarate with 0 mg folic acid
Trial: 33439978
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe as ferrous fumarate with 0.4 mg folic acid
Trial: 33439978
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Fe as ferrous fumarate with 2.8 mg folic acid
Trial: 32885389
Drug: Non‐steroidal anti‐inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐steroidal anti‐inflammatory drugs (NSAIDs)
Trial: 32885389
Drug: Combination biologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination biologic therapy
Trial: 35091727
Drug: Microneedle device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedle device delivered topical steroids
Trial: 35091727
Drug: Topical Daivobet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Daivobet gel (control)
Trial: 32805133
Drug: Roux‐en‐Y gastric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roux‐en‐Y gastric bypass (RYGB) plus medical therapy (MT)
Trial: 32544925
Drug: Kappa-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kappa-opioid receptor (KOR) antagonist for 8 weeks
Trial: 32544925
Drug: Kappa-opioid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kappa-opioid receptor (KOR) antagonist
Trial: 33275278
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium
Trial: 32192678
Drug: Chronic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic low level tragus stimulation (LLTS) at 20 Hz, 1 mA below discomfort threshold for 1 hour daily over 6 months
Trial: 32448804
Drug: Camrelizumab combined
RxNorm normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Camrelizumab combined with apatinib (intermittent dosing)
Trial: 38279575
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg BID
Trial: 35226276
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (220 mg of elemental zinc daily for 24 weeks)
Trial: 35585483
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (DEX)
Trial: 616191571
Drug: Morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine sulfate prolonged release (previous treatment)
Trial: 33010323
Drug: Ciclopiroxolamine 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclopiroxolamine 1% cream
Trial: 36182235
Drug: Accelerated partner
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated partner therapy (usual care plus an offer of accelerated partner therapy)
Trial: 36182235
Drug: Accelerated partner
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated partner therapy
Trial: 35090531
Drug: OptiMA strategy
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OptiMA strategy (ready-to-use therapeutic food at gradually tapered doses)
Trial: 32912971
Drug: Oestrogen treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen treatment (oestradiol hemihydrate 10 μg vaginal pessaries)
Trial: 32912971
Drug: No oestrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oestrogen treatment
Trial: 34064996
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of valine
Trial: 34998508
Drug: i.v. TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. TXA 1 g
Trial: 34998508
Drug: i.m. TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. TXA 1 g
Trial: 34998508
Drug: oral TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral TXA solution 2 g
Trial: 33571267
Drug: Iron containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron containing micronutrient powder supplementation (12.5 mg elemental iron, vitamin A 400 μg, ascorbic acid 30 mg, zinc 5 mg)
Trial: 39271158
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH
Trial: 32961500
Drug: One-day Acceptance
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-day Acceptance and Commitment Therapy workshop
Trial: 34292628
Drug: Promotility drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Promotility drug
Trial: 32294244
Drug: L-PRF +
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF + ABG
Trial: 35984607
Drug: DOT Diary
RxNorm normalized name: D3 Dots
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOT Diary (automated directly observed therapy)
Trial: 35545995
Drug: delafloxacin 300
RxNorm normalized name: delafloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delafloxacin 300 mg
Trial: 33609794
Drug: Janus‐kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Janus‐kinase inhibitors
Trial: 33175637
Drug: Conventional Salk‐IPV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Salk‐IPV (cIPV, 40:8:32 DU/dose)
Trial: 34751757
Drug: Delayed surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed surgical treatment
Trial: 37056360
Drug: Intensive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive statin therapy
Trial: 36459369
Drug: Calcitriol 0.25
RxNorm normalized name: CALCITRIOL 0.25MCG CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol 0.25 µg/day 1 week before parathyroidectomy
Trial: 36123858
Drug: COC2 (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COC2 (30 µg ethinyl estradiol/3 mg drospirenone)
Trial: 35014049
Drug: mOIT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mOIT with total maintenance dose of 1200 mg protein
Trial: 39548608
Drug: Mime therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mime therapy
Trial: 32173642
Drug: New wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New wound dressing combined with Longxuejie capsules
Trial: 32173642
Drug: Longxuejie capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longxuejie capsules (control group)
Trial: 38241661
Drug: COVID-19 vaccine
RxNorm normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 vaccine
Trial: 33852164
Drug: Caffeine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (800 mg total, chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Trial: 33852164
Drug: Placebo (chewed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (chewed gum for 5 minutes at 2-hour intervals over a 6-hour treatment period)
Trial: 38834226
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel (control)
Trial: 32315497
Drug: Topical omiganan
RxNorm normalized name: Omiganan
DrugBank: Omiganan (DB06610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical omiganan 1%
Trial: 36169979
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (1 mg per day) duration-response analysis
Trial: 32265309
Drug: Inhaled aztreonam
RxNorm normalized name: aztreonam Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled aztreonam
Trial: 32088913
Drug: Levetiracetam at
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam at 40 mg/kg over 10 min
Trial: 32088913
Drug: Fosphenytoin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosphenytoin at 20 mg/kg phenytoin equivalents (PE)
Trial: 34103179
Drug: cabazitaxel (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cabazitaxel (20 or 25 mg/m2) in PROSELICA
Trial: 33320753
Drug: Hydrocolloid/hydrogel dressings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocolloid/hydrogel dressings plus 20 exposures to low-level laser therapy (LLLT)
Trial: 36053806
Drug: Molnupiravir 400
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir 400 mg every 12 hours for 5.5 days
Trial: 36053806
Drug: Molnupiravir 800
RxNorm normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Molnupiravir 800 mg every 12 hours for 5.5 days
Trial: 36053806
Drug: Administration with
RxNorm normalized name: Blood Administration with Cair Clamp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration with food
Trial: 32359044
Drug: Incremental cost-effectiveness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incremental cost-effectiveness ratios (ICER) moving from G‐BCT to S‐BCT
Trial: 32359044
Drug: Percentage days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percentage days abstinent, adverse consequences of alcohol and drugs, overall relationship functioning
Trial: 33851461
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa oil (2 g)
Trial: 33497362
Drug: Anti-CD40 monoclonal
RxNorm normalized name: Recombinant anti-CD40 monoclonal antibody
DrugBank: Lucatumumab (DB06360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine
Trial: 33625518
Drug: Topical Timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical Timolol
Trial: 34437553
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy (various attributes assessed)
Trial: 34437553
Drug: Food-drug interaction
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food-drug interaction concern
Trial: 32511774
Drug: Restricted dietary
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Restricted dietary sodium intake (10 mmol/d, 230 mg/d)
Trial: 36846138
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin
Trial: 35192610
Drug: hsCRP 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP 2.0 to 4.9 mg/L
Trial: 38307421
Drug: hsCRP <2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hsCRP <2 mg/L
Trial: 34287833
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cannabidiol (CBD) 20 mg/kg/day, titrated up to 30 mg/kg/day over 2 weeks
Trial: 33455928
Drug: Second-generation antipsychotics
RxNorm normalized name: regenerated cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antipsychotics (SGAs)
Trial: 36146287
Drug: Real-time wearable
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Real-time wearable feedback with daily goal using the Manumeter device for three weeks
Trial: 35090543
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care physical therapy
Trial: 32799922
Drug: tDCS+AMT (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tDCS+AMT (15 min of concurrent tDCS and ankle motor tracking)
Trial: 32482668
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment control group receiving only the therapeutic exercise protocol
Trial: 35534916
Drug: G‐6‐PD‐deficient RBCs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐6‐PD‐deficient RBCs
Trial: 36305963
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic lozenges containing B. lactis HN019
Trial: 33515070
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (in children with the type 1 diabetes‐susceptible INS genotype)
Trial: 36273202
Drug: Nalbuphine 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 80 mg + 0.9% normal saline (72 ml) in patient-controlled analgesia pump
Trial: 36273202
Drug: Morphine 80
RxNorm normalized name: MORPHINE 80MG/NALTREXONE 3.2MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 80 mg
Trial: 33167921
Drug: Activity-oriented proprioceptive
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity-oriented proprioceptive antiedema therapy (TAPA)
Trial: 33167921
Drug: Conventional treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatments (Decongestive Lymphedema Therapy (DLT) or Complex Physical Therapy (CPT))
Trial: 32840417
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 once every 3 weeks (≤ 6 cycles)
Trial: 35120566
Drug: Minocycline 50
RxNorm normalized name: minocycline 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 50 mg orally, followed by 50 mg once a day for 5 days
Trial: 32133487
Drug: Intravenous ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ceftriaxone 2 g daily for 3 weeks
Trial: 35377557
Drug: Transdiagnostic Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic Cognitive Behavioral Therapy (TCBT) during eight sessions provided by trained general health service providers
Trial: 35437030
Drug: Acupuncture (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture (12 treatment sessions over 4 weeks)
Trial: 35437030
Drug: Sham acupuncture
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham acupuncture (12 treatment sessions over 4 weeks)
Trial: 32641335
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of different UF and sodium profiling strategies through individualised dialysate sodium concentration
Trial: 35834252
Drug: mAb treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mAb treatment (casirivimab-imdevimab or sotrovimab)
Trial: 33046611
Drug: Interaction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interaction of treatment allocation and WML severity
Trial: 35896211
Drug: Oral imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral imatinib
Trial: 34912506
Drug: 200 mL/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL/day low-fat milk
Trial: 34912506
Drug: 30 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g/day pistachio
Trial: 36000541
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (standard of care)